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Tumor-associated antigens (TAAs) recognized by cellular and/or humoral effectors of the immune system are
attractive targets for diagnostic and therapeutic approaches to human cancer. Different approaches can be used to
comprehensively characterize and validate the identified TAA/anti-TAA systems, which are potential biomarkers in
cancer immunodiagnosis. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The
high fatality rate of HCC within one year after its detection might be partly attributed to a lack of diagnostic
methods that enable the early detection. Our previous studies have shown that novel autoantibodies can appear
which are not detected prior to pre-malignant conditions during transition from chronic liver disease to HCC. The
hypothesis we advance is the transition to malignancy can be associated with autoantibody response to certain
cellular proteins that might have some role in tumorigenesis. We propose that the information that the cancer
patient’s immune system is conveying in the form of autoantibodies to tumor-associated antigens (TAAs) should be
utilized to a greater extent in identifying early signs of tumorigenesis. In this review, we will focus on the important
features of TAA and the possibility that autoantibodies to TAAs can be used as biomarkers in immunodiagnosis and
prognosis of HCC.
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Hepatocellular carcinoma (HCC) is the third most
common cause of cancer-related death worldwide. The
majority of people with HCC will die within one year
since they have been made a definite diagnosis. The high
fatality rate of HCC can partly be attributed to a lack of
sensitive detection method for HCC early diagnosis.
Serum alpha fetoprotein (AFP) is the most effective
marker available to detect HCC, however the sensitivity
and specificity are not optimal, especially in patients
with small tumors or in well-to-moderately differenti-
ated HCC [1-3]. Therefore, it is necessary to develop
more sensitive and specific methods for supplementing
AFP in the early detection of HCC.* Correspondence: jzhang@utep.edu
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reproduction in any medium, provided the orThere are many studies demonstrating that the im-
mune system can recognize the antigenic changes in
cancer cells, and further develop autoantibodies against
these antigens which have been called tumor-associated
antigens (TAAs) [4,5]. Therefore, these cancer-associ-
ated autoantibodies might be considered as “reporters”
from the immune system, to identify the antigenic
changes of cellular proteins involved in the transform-
ation process [2,5]. Research on autoantibody immunity
to cancer-associated proteins has received great atten-
tion. As the detection of antibody immunity to tumor
antigens becomes more routine, investigators have
begun to address specific clinical application of cancer-
associated autoantibody as a marker for detection of
cancer, as a tool to monitor therapy, or as an indicator
to predict disease prognosis. With the expending list of
autoantibodies to TAAs, the identification of cancer-
associated autoantibody signatures may therefore. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nosis [6-8].
The purpose of this review will focus on the recent ad-
vances in our studies primarily associated with the idea
and possibility that detection of anti-TAAs autoanti-
bodies can be useful for HCC immunodiagnosis.
This study was approved by the Institutional Review
Board of The University of Texas at El Paso and collab-
orating institutions.
Tumor-associated antigens (TAAs) and
autoantibodies
One of the most extensively studied TAAs is p53, the
tumor suppressor protein, which is a phosphoprotein
barely detectable in the nucleus of normal cells [9]. P53
can arrest cell-cycle progression on cellular stress, par-
ticularly induced by DNA damage, to allow the DNA to
be repaired [10] or trigger a process that can lead to cell
apoptosis [11]. Autoantibodies to p53 in cancer were
first reported in 1982 [12] and since then there have
been numerous reports confirming and extending this
finding [13]. Antibodies to p53 have now been found in
many types of cancer, including lung [14], esophageal
[15], oral [16], colon [17], gastric [18], hepatic [19],
breast [20] cancers. A review article demonstrated that
p53 antibodies are a specific marker of patients with ma-
lignancy [13]. For several tumor sites a decline or even
disappearance of p53 antibody levels few weeks after
surgical tumor removal has been demonstrated, which is
in line with the hypothesis that constant stimulation of
the immune system by the antigen is necessary to main-
tain high antibody levels [21-24]. These findings led to
the suggestion that antibody serology might be a tool for
detection of disease recurrence [25].
The types of cellular proteins inducing autoantibody
responses are quite varied and include oncogene prod-
ucts such as HER-2/neu [26], cellular proteins which
shield mRNAs from natural physiological degradation
such as p62/IMP2 [27] and CRD-BP [28], onconeural
antigens in the paraneoplastic disorder syndrome [29],
differentiation-antigens such as tyrosinase and cancer/
tetis antigens [30].
The approach used in our laboratory to identify TAAs
has involved initially examining the sera from cancer pa-
tients using extracts of tissue culture cells as source of
antigens in Western blotting or by indirect immuno-
fluorescence (IIF) on whole cells. With these two tech-
niques, sera with high-titered fluorescent staining and
strong signals to cell extract have been identified and
subsequently used as probes to immunoscreen cDNA
expression libraries and isolate cDNA clones encoding
targeted antigens. HCC1 [31], p62/IMP2 [27], p90 [32]
and other several novel TAAs have been identified in
this manner.A major issue in the field of cancer immunodiagnosis
is the definition of what constitutes a TAA. It is
erroneous to include all cellular antigens identified by
autoantibodies in cancer sera as TAAs, since some auto-
antibodies may exist in conditions that pre-date malig-
nancy. Many antibodies to autologous cellular proteins
can be detected in the sera of patients with cancer, and
the reactive antigens have been called TAAs without
considering the possibility that the autoantibodies might
have existed in the patient before cancer. It indicates
that autoantibodies from a cancer patient obtained at
only one time point would not be necessarily represent
immune responses to a TAA. Failing to recognize the
likelihood of pre-malignant circulating antibodies would
result in the inclusion of many antigens erroneously as
TAAs. Further research should be needed to establish
true tumor-related antigens and to exclude those that
might have been present prior to malignancy. In the fur-
ther analysis, anti-TAA autoantibodies may become use-
ful diagnostic biomarkers only after it has undergone
extensive trials with many cancer sera and also with
many non-cancer control sera [33].
Hepatocellular carcinoma (HCC) is one of unique can-
cers since it could be followed up from a cohort of pa-
tients with chronic liver disease who will likely develop
malignancy over a period time more than one decade.
During transition from chronic liver disease to malig-
nancy, novel autoantibodies have been observed to ap-
pear which are not detected prior to pre-malignant
conditions [34]. As mentioned above, our previous stud-
ies have identified several novel TAAs including HCC1
[31], p62/IMP2 [27] and p90 [32], which might be po-
tential biomarkers in cancer immunodiagnosis. Below
will be a brief discussion of the identification and signifi-
cance of each TAA we have identified in HCC.
HCC1/CAPER
HCC1/CAPER is the first HCC-associated TAA isolated
and identified [31]. Serum from a patient NK at the time
when cancer was diagnosed was used to immunoscreen
a HepG2 cell line λ - zap cDNA expression library in
attempt to clone genes encoding any of the protein anti-
gens. HCC1/CAPER, one of six cDNA clones which
were all different-length isolates, has a full-length se-
quence, encoding a protein of 530 amino acid and mi-
grating at 64 kDa in SDS-PAGE. HCC1/CAPER was a
novel gene with unknown function at that time since the
nucleotide and protein sequences were not found in
Genbank and EMBL and SwissProt databanks. HCC1/
CAPER contained a RS (arginine-serine) motif in the
NH-terminus and three RNA-binding, RNP-CS (ribonu-
cleoprotein consensus sequence, which has paired RNP1
and RNP2 regions) in the rest of the molecule. The
structural peptide motifs of HCC1/CAPER were most
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whose function was already characterized and shown to
be an alternative splicing factor involved in pre-mRNA
processing [31]. Other proteins with somewhat similar
domain structure, such as SC35 [35] and SF2/ASF [36]
and SRp55 [37], were also splicing factors involved in
mRNA processing. However, the role of HCC1/CAPER
in constitutive splicing is poorly understood. And there
was no indication as to how it might be involved in
tumorigenesis.
Nine years later, Jung et al reported that HCC1/
CAPER was a co-activator of activating protein-1 and
estrogen receptors and proposed naming it CAPER [38].
Three years after that, O’Malley and his colleagues
shows that HCC1/CAPER was also an alternative spli-
cing factor involved in the regulation of calcitonin and
Vascular endothelial growth factor (VEGF) gene expres-
sion [39,40], confirming function that was expected of
its peptide motifs. More interestingly, a recent study has
reported that HCC1/CAPER may an important role in
modulating the oncogenic activity of Rel/NF-kB, sugges-
ting that a dominant-negative mutant of HCC1/CAPER
enhanced vRel-mediated transformation [41]. In a recent
study, autoantibody responses to HCC1 were extensively
evaluated in sera from patients with HCC, liver cirrhosis
and chronic hepatitis, and other type of cancer. The
prevalence of autoantibodies against HCC1 was 20.1% in
HCC sera, which was significantly higher than that in
NHS (2.3%), but not for other type of cancer (unpub-
lished data). With the further understanding of the func-
tion of HCC1/CAPER, we may consider HCC1/CAPER
as a candidate TAA. Actually, it is almost 15 years later
after the first report of the identification of HCC1/
CAPER in liver cancer.p62/IMP2 (IGF-II mRNA binding protein)
p62/IMP2 was firstly identified as an autoantigen by
screening the sera from patients with HCC [27]. Later
studies found that p62/IMP2 is a member of the IGF-II
mRNA binding protein (IMP) family, containing four
hnRNP K-homology (KH) domains and two RNA recog-
nition motifs [42]. It is encoded by a splice variant of the
IMP2 gene, thus is known as an IMP2 isoform. The IMP
family (IMP1, IMP2 and IMP3) binds and regulates
translation of insulin-like growth factor 2 mRNA. Mem-
bers of this family are oncofetal proteins [43], which
have been implicated in RNA localization, stability and
translation that are essential for normal embryonic
growth and development. The expression disappears
from all tissues soon after birth but frequently re-
express during the process of malignant transformation.
The overexpression of these proteins has been detected
in many types of tumors, [27,44,45] and it has beenhypothesized that the proteins can mediate cell motility
and invasion, and might be closely related to cancer.
Antibody to p62/IMP2 was present in 21% of patients
with HCC but not in the precursor conditions of chronic
hepatitis and liver cirrhosis [27]. Other proteins from
the IMP family also show certain relationship to malig-
nancy. IMP1, which is almost identical to mouse coding
region determinant-binding protein (CRD-BP) [46] and
closely related to chicken zip-code binding protein 1
(ZBP1), binds directly to and stabilizes oncogenic c-Myc
and regulates its posttranscriptional expression and
translation [47,48]. IMP3 is orthologous to Xenopus
Vg1RBP/Vera and mouse K-homology protein overex-
pressed in cancer (KOC), which has been shown to be
transcriptionally overexpressed in cancer [49].
p90/CIP2A (Cancerous Inhibitor of PP2A)
CIP2A is another tumor-associated antigen migrating in
SDS-PAGE gel as a protein of 90 kD (also known as
p90) [32]. It was firstly identified when screening sera
from patients with gastric and liver cancer [32]. This
protein has been shown to inhibit PP2A (Protein phos-
phatase 2) function, as a result stabilize the oncogene
c-myc in human malignancies. Phosphorylation is a key
kind of posttranscriptional modifications, which is also
critical for the process of malignancy. PP2A exerts its
tumor suppressive effects through dephosphorylating
substrates at Serine and Threonine residues. Current un-
derstandings of the role of p90/CIP2A in tumor forma-
tion and progression mainly focus on its ability to
inhibit PP2A phosphatase activity to regulate c-myc sta-
bility [50]. Several groups have confirmed the import-
ance of p90/CIP2A in tumor formation in different
cancer types like breast cancer, prostate cancer, gastric
cancer, non-small cell lung cancer, oral carcinoma,
esophageal squamous cell carcinoma and chronic mye-
loid leukemia [51-57].
Approaches to TAAs identification
Autoantibodies to TAAs have been reported in a variety
of human cancers, providing an insight into the interplay
between malignancies and the immune response, and
giving rise to novel diagnostic and therapeutic concepts
[5]. Experimental technologies for identification of
tumor-associated antigens include display methods such
as phage display, serological expression cloning analysis,
and TAA arrays [58,59]. The approaches we once used
in identifying the TAAs involved examining the sera of
cancer patients using extracts of tissue or cultured cells
as a source of antigens in Western blotting or by indir-
ect immunofluorescence on whole cells. These two com-
monly used techniques have helped us to identify sera
which have strong signals on Western blotting or high
fluorescent staining, and subsequently use the antibodies
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sion libraries. In this case, several novel TAAs including
HCC1/CAPER [31], SG2NA [60], p62/IMP2 [27], p90/
CIP2A [32] were identified.
Serological analysis of recombination cDNA expres-
sion libraries (SEREX) [61] is a useful methodology in
identifying tumor antigens to autoantibodies from
patients with different types of cancer [5], which is a
modified technology of our previously used approach
[27,31,32,60]. The rational of this method is that intra-
cellular proteins which are involved in carcinogenesis
are provoking autoantibody responses and therefore
autoantibodies can be used to immunoscreen cDNA ex-
pression libraries to isolate, identify and characterize
proteins which might potentially be involved in malig-
nant transformation. SEREX has proven to be a powerful
tool in identifying antibody targets in a number of tumor
types, including lymphoma, leukemia, esophageal cancer,
gastric cancer, etc. [62,63]. The number of SEREX-
defined antigens exceeds 2000 kinds, with approximately
one-third defining novel genes at the time of their dis-
covery [64]. Our approach was not restricted to use of
cDNA libraries from autologous tumors because our
previous studies had shown that antibodies in HCC sera
were reactive with antigens expressed by a variety of tis-
sue culture cell lines [27,31]. Using this approach, we
have successfully isolated several novel TAAs such as
p62/IMP2 and p90/CIP2A.
An improvement of SEREX approach is to combine it
with phage-display technology. The phage-display technol-
ogy has been widely used since it was first introduced in
1985 [65]. It’s capable to generate and screen peptide librar-
ies to identify ligands for many types of molecules. Screen-
ing the phage-displayed libraries needs fewer amounts of
sera from patients and has higher efficiency. Tumor cell
lines have been used as source of cDNA to construct phage
display libraries to identify candidate TAAs in colorectal,
breast, prostate, and ovarian cancer [59].
In recent years, proteomics have become a rapidly
emerging set of technologies to identify TAAs [66]. The
proteome-based methods enable us to screen a large
number of sera individually and determine a large num-
ber of autoantigens. An advantage of this approach is to
distinguish isoforms and detect autoantibodies directly
against post-translational modifications (PTMs) of spe-
cific targets. In our experience, two-dimensional gel
electrophoresis and mass spectrometry can be used to
separate lysates from cancer cell lines and identify im-
munoreactive proteins. In recent several years, we have
identified characterized a bunch of protein in HCC and
other type of cancer as TAAs with proteomic approach
[67,68]. A schematic representation of the approaches
for the TAA identification used in our lab has been pub-
lished [69].Using a mini-array of multiple TAAs to enhance
autoantibody detection in HCC diagnosis
The unique feature of HCC is that antecedent chronic
hepatitis and liver cirrhosis are common precursor con-
ditions and during transition to malignancy some pa-
tients develop autoantibodies which are not present
during preceding chronic liver disease phase [34,70,71].
It was shown that novel autoantibodies appeared during
conversion to malignancy which were not present in the
pre-malignant chronic liver disease phase. In HCC,
where novel autoantibody responses are detected during
conversion to malignancy, it has been proposed that
characterization of the autoantigens driving the novel
immune responses might provide insights into intracel-
lular proteins participating in mechanisms leading to
malignant transformation [1]. Many researchers have
been interested in the use of autoantibodies as sero-
logical markers for cancer diagnosis, especially because
of the general absence or a significantly lower frequency
of these autoantibodies in normal individuals and in
non-cancer conditions [7,72]. Enthusiasm for this ap-
proach has been tempered by low sensitivity when indi-
vidual antigen-antibody reactions were studied.
Antibody frequency to any individual TAA was vari-
able but rarely exceeded 15-20% [7,73]. We have ob-
served that this drawback can be overcome by using a
panel of carefully selected TAAs to achieve the sensitiv-
ity and specificity required to make immunodiagnosis a
feasible adjunct to tumor diagnosis. This feature is one
of the innovative notions in our studies. Previous obser-
vations show that antibodies to any individual antigen
such as p53 [7], c-myc [7,74], p62 [7] do not reach levels
of sensitivity which could become routinely useful in
diagnosis. Wang et al developed a phage-display library
derived from prostate cancer tissue, and a phage protein
microarray, to analyze autoantibodies in serum samples
from patients with prostate cancer and controls [72]. In
this study, a 22-phage-peptide detector was constructed
for prostate cancer screening, with 81.6% sensitivity and
88.2% specificity, which indicated that combinations of
multiple antigen-antibody systems might acquire higher
sensitivity for diagnosis of cancer [72]. One of our previ-
ous studies showed that detection of autoantibodies in
cancer can be enhanced by using a mini-array of seven
TAAs as target antigens which included c-myc, p53, cyc-
lin B1, p62/IMP2, Koc, IMP1 and survivin [7,73]. Anti-
body frequency to any individual TAA ranged from 10.8
to 24.6% in HCC. With the addition of TAAs to a final
total of seven antigens, there was a stepwise increase of
positive antibody reactions up to 56.9% in HCC. In our
further study, p16, a cyclin-dependent kinase inhibitor,
was evaluated as a TAA and added into our previously
constituted mini-array of seven TAAs. Antibody fre-
quency to any individual TAA in HCC was variable from
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wise increase of positive antibody reactions up to 59.9%
with successive addition of TAAs to a final of eight anti-
gens, which was significantly higher than the frequency
of antibodies in chronic hepatitis (20%), liver cirrhosis
(30%) and normal individuals (12.2%). The sensitivity on
diagnosing HCC was 59.9%, and the specificity was
87.8%, 80% and 70%, respectively, compared to normal
individuals, chronic hepatitis and liver cirrhosis [75].
The data from our studies indicates that the combin-
ation of antibodies might acquire higher sensitivity for
diagnosis of cancer.
Nevertheless, in the selection of different antigen-
antibody systems, some of the antigens may turn out to
be more specific for a certain type of cancer while others
may be not. It is conceivable that autoantibody profiles
involving different panels or arrays of TAAs might be
developed and the results could be useful for diagnosis
of certain types of cancer. We stress the notion that
panels of “customized” TAAs should be used for differ-
ent types of tumor and that these customized panels
should be rigorously tested for sensitivity and specificity
not only against other tumors but also against other dis-
eases conditions. In the case of HCC, the natural condi-
tions could be chronic hepatitis and liver cirrhosis. The
basis for the notion of the necessity of customized
panels of TAAs is based not only on empirical observa-
tions but also on retrospective analysis of our own data
learned from previously published work [7,34,71,73].
The main focus of our studies is to identify a specific
panel of TAAs for HCC and compare and contrast this
with antigen panels associated with chronic hepatitis
and liver cirrhosis.
Possibility for anti-TAAs antibody as prognosis
indicator
It is of great importance to find early detection of cancer
in clinical oncology, which allows an effective and prob-
ably curative therapeutic management [10]. In the mean-
while, the prognosis of a patient diagnosed with cancer
is considered as the chance that the disease will be cured
and the patient will recover. It is known that various fac-
tors can affect the prognosis of a patient with cancer, in-
cluding the biological and genetic properties of the
cancer cells, which are also known as biomarkers and
can be determined by certain tests. The potential utility
of anti-TAAs antibody as early cancer biomarker or indi-
cators of disease prognosis has been explored, since
these anti-TAA antibodies are generally absent, or
present in low frequency in normal individuals and in
non-cancer conditions.
More and more evidences have shown that the im-
mune system of the cancer patient is able to sense ab-
normalities in structure, function, intracellular locationand other alterations of cellular participants in tumori-
genesis [2]. Although most current studies are focusing
on cancer autoantibodies as diagnostic biomarkers, it is
likely that autoantibodies can also be used as monitors
of therapeutic response, thus contributing to cancer
prognosis. It is hypothesized that in a patient where a
certain anti-TAA antibody is detected, change in anti-
body levels might reflect change in tumor status or
tumor burden related to therapy [2].
Currently, although the continuous development
and progress have been made in early diagnosis and
treatment of cancer, however we are still facing prob-
lems to find sensitive and accurate biomarkers for
cancer diagnosis, prognosis and treatment. Molecular
studies using TAA-based arrays have identified several
cancer related proteins involved in cell proliferation
and metastasis during the process of tumorigenesis
[76]. Such proteins have been detected in patients’
serum, which distinguish diseased individuals from
healthy controls. Using TAA-array technique might
be a useful tool to determine the groups of cancer
patients with certain clinical outcomes, and conse-
quently benefit to personalized treatment. Thus, it is
of great importance to determine reliable biomarkers
with high prognostic value.Conclusions
In the past few years, the potential utility of autoanti-
body to TAAs as cancer biomarker for early detection or
as indicators of disease prognosis has been explored.
Our efforts will be aimed at increasing both the sensitiv-
ity and specificity of antibodies as markers in HCC by
expending TAA array to include antigens which might
be more selectively associated with HCC and not with
others. It is expected that our mini-array of multiple
TAAs can be used as a novel non-invasive approach to
identify HCC in normal population and also in high-risk
individuals such as patients with chronic hepatitis and
liver cirrhosis. We predict that, in the next five years,
the research on the cancer TAA autoantibody bio-
markers will become a challenging field. With the data
at hand, we know that many TAAs are not unique to
any particular type of solid tumor and this should not be
unexpected since tumorigenesis pathways are common
to many tumors. Waiting for the generation of TAA ar-
rays for immunodiagnosis of specific cancers, however,
should not preclude taking advantage of the sensitivity
of the anti-TAA/TAA systems in the initial screening
process for early detection of cancer. Important add-
itional studies will be needed to determine whether anti-
bodies to a mini-arrays of multiple TAAs might be
useful in identifying in early stage of certain types of
other cancer in high-risk individuals.
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